Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Interest Coverage 5.81
STJ's Interest Coverage is ranked lower than
99.99% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 71.12 vs. STJ: 5.81 )
Ranked among companies with meaningful Interest Coverage only.
STJ' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.81
Current: 5.81
0
5.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» STJ's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

STJ Guru Trades in Q2 2016

George Soros 38,860 sh (New)
Joel Greenblatt 46,348 sh (New)
John Paulson 45,500 sh (New)
Richard Perry 265,000 sh (New)
Paul Tudor Jones 331,990 sh (New)
Manning & Napier Advisors, Inc 32,887 sh (New)
Mario Gabelli 74,400 sh (+785.71%)
Leucadia National 20,000 sh (+325.53%)
Jeremy Grantham 1,372,968 sh (+81.33%)
Vanguard Health Care Fund 6,123,679 sh (unchged)
Jeff Auxier 31,973 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Steven Cohen Sold Out
Ray Dalio Sold Out
Mairs and Power 2,912,404 sh (-0.82%)
David Dreman 16,913 sh (-3.51%)
Ken Fisher 237,317 sh (-8.13%)
John Rogers 959,830 sh (-48.14%)
Keeley Asset Management Corp 12,220 sh (-48.98%)
Jim Simons 150,000 sh (-92.19%)
» More
Q3 2016

STJ Guru Trades in Q3 2016

First Eagle Investment 545,389 sh (New)
Daniel Loeb 2,600,000 sh (New)
Eric Mindich 1,467,100 sh (New)
Paul Singer 250,249 sh (New)
Leucadia National 53,200 sh (+166.00%)
John Paulson 94,500 sh (+107.69%)
Manning & Napier Advisors, Inc 33,297 sh (+1.25%)
Vanguard Health Care Fund 6,123,679 sh (unchged)
Paul Tudor Jones 400,000 sh (unchged)
Ken Fisher Sold Out
George Soros Sold Out
Keeley Asset Management Corp Sold Out
Richard Perry Sold Out
Jim Simons Sold Out
Mairs and Power 2,892,464 sh (-0.68%)
Jeff Auxier 31,374 sh (-1.87%)
Jeremy Grantham 1,244,444 sh (-9.36%)
Mario Gabelli 66,900 sh (-10.08%)
Paul Tudor Jones 157,700 sh (-52.50%)
Joel Greenblatt 6,069 sh (-86.91%)
John Rogers 94,498 sh (-90.15%)
David Dreman 51 sh (-99.70%)
» More
Q4 2016

STJ Guru Trades in Q4 2016

George Soros 52,386 sh (New)
Jim Simons 1,310,913 sh (New)
Paul Tudor Jones 507,358 sh (+221.72%)
Eric Mindich 3,169,724 sh (+116.05%)
Manning & Napier Advisors, Inc 35,664 sh (+7.11%)
Mario Gabelli 71,350 sh (+6.65%)
Jeff Auxier 31,525 sh (+0.48%)
Vanguard Health Care Fund 6,123,679 sh (unchged)
David Dreman Sold Out
Leucadia National Sold Out
First Eagle Investment Sold Out
Joel Greenblatt Sold Out
John Rogers Sold Out
John Paulson Sold Out
Daniel Loeb Sold Out
Paul Singer Sold Out
Mairs and Power 2,869,605 sh (-0.79%)
Jeremy Grantham 730,986 sh (-41.26%)
» More
Q1 2017

STJ Guru Trades in Q1 2017

Vanguard Health Care Fund Sold Out
Mario Gabelli Sold Out
George Soros Sold Out
Jeremy Grantham Sold Out
Jeff Auxier Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mairs and Power Sold Out
Manning & Napier Advisors, Inc Sold Out
Eric Mindich Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with STJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-03-31 Sold Out 1.18%$80.69 - $80.82 $ 80.51-0%0
George Soros 2017-03-31 Sold Out 0.14%$80.69 - $80.82 $ 80.51-0%0
Mario Gabelli 2017-03-31 Sold Out 0.04%$80.69 - $80.82 $ 80.51-0%0
Mario Gabelli 2016-12-31 Add 6.65%$77.44 - $81.28 $ 80.511%71,350
George Soros 2016-12-31 New Buy0.14%$77.44 - $81.28 $ 80.511%52,386
Joel Greenblatt 2016-12-31 Sold Out 0.01%$77.44 - $81.28 $ 80.511%0
John Paulson 2016-12-31 Sold Out 0.08%$77.44 - $81.28 $ 80.511%0
Leucadia National 2016-12-31 Sold Out 0.35%$77.44 - $81.28 $ 80.511%0
John Rogers 2016-12-31 Sold Out 0.09%$77.44 - $81.28 $ 80.511%0
David Dreman 2016-12-31 Sold Out $77.44 - $81.28 $ 80.511%0
First Eagle Investment 2016-12-31 Sold Out 0.11%$77.44 - $81.28 $ 80.511%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., XSWX:SOON, NYSE:TFX, NYSE:VAR, NAS:ABMD, ASX:COH, OCSE:WDH, NYSE:BSX, XPAR:DIM, SZSE:300003, NZSE:FPH, LSE:CTEC, NAS:MASI, OCSE:GN, OSTO:EKTA B, NAS:ISRG, OCSE:AMBU B » details
Traded in other countries:JUD.Germany,
Headquarter Location:USA
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.

St Jude Medical Inc was incorporated in Minnesota in 1976. It develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Company's two segments are the Implantable Electronic Systems Division and the Cardiovascular and Ablation Technologies Division. The Company's principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) - tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) - vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, cardiac mapping, navigation and recording systems and ablation systems). Implantable Electronic Systems Division (IESD): IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. Cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program is cardiac rhythm management devices and analyze device data to improve patient management. Neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical current directly to targeted nerve sites. The Company's commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. A neurostimulation system typically consists of four components: a pulse generator that produces the electrical current and is implanted under the patient's skin; implanted leads that carry the electrical impulses to the targeted nerve sites; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician pro

Top Ranked Articles about St Jude Medical Inc

Abbott Labs Declares Quarterly Dividend Global health care company will pay its shareholders 26.5 cents per share
Abbott Laboratories (NYSE:ABT) announced a regular quarterly dividend of 26.5 cents per share June 9. Read more...
Mairs and Power Finds Value and Growth Close to Home This Minnesota-based firm tries to find companies based in the Upper Midwest so it can get to know them, have better access to management
Every guru finds a route to success, some unique edge in identifying reasonably priced companies that have more potential than average. Read more...
Abbott Laboratories Declares Quarterly Dividend Analysts' forecast increases for EPS and sales
Abbott Laboratories (NYSE:ABT) announced a regular quarterly dividend of 26.5 cents per share on Feb. 17. Read more...
FDA Approves Abbott Labs' Devices for MRI Scans Patients with Assurity MRI pacemaker or Tendril MRI pacing lead can have full-body scans
Good news for heart patients implanted with Abbott Labs’ (NYSE:ABT) Assurity MRI pacemaker and Tendril MRI pacing lead. The U.S. Food and Drug Administration (FDA) has approved the two devices for total-body MRI scans. Read more...
Abbott Closes St. Jude Medical Deal Wednesday The purchase will add to company's EPS in 2017
Abbott Labs (NYSE:ABT) communicated through the PRNewswire on Dec. 30 that the closure of the purchase of St. Jude Medical (NYSE:STJ) for $25 billion is expected on Wednesday. Read more...
Abbott Labs to Buy St. Jude Medical for $25 Billion Company agreed on US FTC conditions for the closing of the deal
Abbott Labs (NYSE:ABT) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical (NYSE:STJ) for a total consideration of $25 billion. Read more...
Abbott Laboratories Announces Quarterly Dividend Health care company increased dividend by 1.9%
The board of Abbott Laboratories (NYSE:ABT) declared through PR Newswire Friday a dividend increase for the last quarter of the year. Read more...

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.52
STJ's Dividend Yield % is ranked higher than
57% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 1.38 vs. STJ: 1.52 )
Ranked among companies with meaningful Dividend Yield % only.
STJ' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.52
Current: 1.52
0
1.52
Dividend Payout Ratio 0.54
STJ's Dividend Payout Ratio is ranked lower than
56% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 0.36 vs. STJ: 0.54 )
Ranked among companies with meaningful Dividend Payout Ratio only.
STJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.54
Current: 0.54
0
0.54
Forward Dividend Yield % 1.53
STJ's Forward Dividend Yield % is ranked higher than
57% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. STJ: 1.53 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.52
STJ's 5-Year Yield-on-Cost % is ranked higher than
50% of the 244 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. STJ: 1.52 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
STJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.52
Current: 1.52
0
1.52

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $5,956.00
EPS (TTM) $ 2.28
Short Percentage of Float2.41%
52-Week Range $48.83 - 84.00
Shares Outstanding (Mil)285.72

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 6,042 6,298 6,721
EPS ($) 4.03 4.36 4.81
EPS without NRI ($) 4.03 4.36 4.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.51%
Dividends per Share ($) 1.08 1.12 1.42

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}